| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,480 | -4,790 | -8,520 | -6,240 | -1,990 |
| Net Income Growth | +27.35% | +43.78% | -36.54% | -213.57% | unch |
Scisparc Ltd ADR (SPRCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company. It focuses on the development of cannabinoid-based treatments. The company's drug development programs based on tetrahydrocannabinol and non-psychoactive cannabidiol includes THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain and THX-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd., formerly known as Therapix Biosciences Ltd., is based in TEL AVIV, Israel.